NIVOLUMAB

Brand name:

• Opdivo®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Submission sponsor:

Bristol-Myers Squibb Australia Pty Ltd

Condition/indication:
(therapeutic use)

• Melanoma

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC Submission type:

Change to listing (Minor)

Comment:

--

Other PBAC consideration:

• NIVOLUMAB

Submission received for:

Not applicable

Opportunity for consumer comment:

Not applicable

PBAC meeting:

Held on 06/11/2019

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

02/12/2019

Lodgement of required documentation:

10/12/2019

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 19/12/2019

Status:

Finalised

Government processes:

Commenced on 21/01/2020

Medicine listed on the PBS:

01/03/2020 (see PBS schedule)